Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) CEO Deborah Knobelman sold 24,838 shares of Kronos Bio stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $0.87, for a total transaction of $21,609.06. Following the completion of the transaction, the chief executive officer now owns 139,422 shares of the company's stock, valued at $121,297.14. This trade represents a 15.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Kronos Bio Stock Down 0.2%
NASDAQ KRON traded down $0.00 on Monday, hitting $0.87. 714,004 shares of the stock were exchanged, compared to its average volume of 373,578. Kronos Bio, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $1.60. The company has a market cap of $53.04 million, a PE ratio of -0.61 and a beta of 1.63. The company has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.89.
Kronos Bio (NASDAQ:KRON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.13). The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million. Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. As a group, equities research analysts predict that Kronos Bio, Inc. will post -1.36 EPS for the current fiscal year.
Hedge Funds Weigh In On Kronos Bio
A number of large investors have recently bought and sold shares of the company. Velan Capital Investment Management LP purchased a new position in Kronos Bio in the fourth quarter valued at about $33,000. GTS Securities LLC purchased a new stake in shares of Kronos Bio during the 4th quarter worth approximately $48,000. Squarepoint Ops LLC purchased a new stake in shares of Kronos Bio during the 4th quarter worth approximately $93,000. Deuterium Capital Management LLC purchased a new stake in shares of Kronos Bio during the 1st quarter worth approximately $121,000. Finally, Kennedy Capital Management LLC boosted its stake in shares of Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock worth $142,000 after acquiring an additional 12,007 shares in the last quarter. Hedge funds and other institutional investors own 64.09% of the company's stock.
Kronos Bio Company Profile
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
